BI rolls out Spiriva Respimat asthma inhaler to pharmacies
RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals Inc. has released Spiriva Respimat, an asthma treatment, to U.S. pharmacies. BI noted that Spiriva Respimat isn’t a medication for sudden asthma symptoms. The Food and Drug Administration approved a once-daily dose of Spiriva Respimat 2.5 µg (delivered in two puffs of 1.25 µg each) for the long-term maintenance
